What is the appropriate treatment for a 15‑year‑old patient with typhoid fever?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Typhoid Fever in a 15-Year-Old Patient

For a 15-year-old with typhoid fever, azithromycin or ceftriaxone should be the first-line treatment, with the specific choice guided by local antimicrobial resistance patterns—particularly fluoroquinolone and cephalosporin resistance rates in your region.

Treatment Algorithm Based on Resistance Patterns

If Local Resistance Data Available:

For quinolone-resistant strains (most common scenario):

  • First choice: Azithromycin 1
  • Second choice: Ceftriaxone 1

For multidrug-resistant (MDR) strains:

  • Fluoroquinolone (if susceptible) OR cefixime OR azithromycin 1

For extensively drug-resistant (XDR) strains:

  • Azithromycin and/or meropenem 2

Evidence Supporting This Approach:

The WHO 2012 guidelines recommend fluoroquinolones as first-line for children, with third-generation cephalosporins or azithromycin as second-line for poor response 1. However, this recommendation is outdated given current resistance patterns—fluoroquinolone resistance is now widespread, with recent data showing 60-73% resistance rates to ciprofloxacin and related quinolones 3.

Azithromycin demonstrates superior outcomes compared to fluoroquinolones, with lower clinical failure rates (OR 0.48) and shorter hospital stays (-1.04 days), plus significantly lower relapse rates compared to ceftriaxone (OR 0.09) 1. Critically, recent surveillance shows zero resistance to azithromycin among S. typhi isolates 3.

Ceftriaxone remains highly effective with 91-99% sensitivity rates 3, and demonstrated better outcomes than cefotaxime in pediatric MDR typhoid (faster defervescence, better cure rates) 4. A 14-day course of ceftriaxone successfully treats most hospitalized children with MDR typhoid 4.

Critical Pitfalls to Avoid:

  • Do not use ciprofloxacin or other fluoroquinolones empirically without susceptibility data—resistance rates exceed 60-73% in recent studies 3, and a trial was stopped early due to high-level fluoroquinolone resistance 1
  • Avoid chloramphenicol, amoxicillin, or trimethoprim-sulfamethoxazole as first-line despite retained in vitro sensitivity (95-99%) 3—these are outdated options reserved for fully sensitive strains only 1
  • Do not use short fluoroquinolone courses (like the historical 3-5 day ofloxacin regimens 5) given current resistance patterns

Dosing and Duration:

While specific dosing isn't detailed in the guidelines provided, standard regimens are:

  • Azithromycin: 10-20 mg/kg/day for 5-7 days
  • Ceftriaxone: 75 mg/kg/day IV for 10-14 days 4

Special Considerations for This Age Group:

At 15 years old, this patient is an adolescent where both pediatric and adult treatment principles apply. The evidence shows no significant differences in treatment response between children and adults 1. Monitor for atypical presentations—pancytopenia, severe electrolyte imbalances (hyponatremia/hypokalemia), cholestatic hepatitis, and pleural effusion can occur and may mimic other infections like tuberculosis in endemic regions 6.

When to Escalate Therapy:

If fever persists beyond 5-7 days on appropriate therapy, consider:

  • Obtaining blood culture with antimicrobial susceptibility testing
  • Switching from azithromycin to ceftriaxone or vice versa
  • For confirmed XDR strains, adding or switching to carbapenem (meropenem or investigational oral tebipenem) 2

The combination strategy of azithromycin plus cefixime is currently under investigation in the ACT-SA trial for targeting both intracellular and extracellular bacteria 2, but is not yet standard of care.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.